Suppr超能文献

胰肾联合移植中胰腺静脉引流部位对患者及移植物长期预后的影响。

Impact of pancreatic venous drainage site on long-term patient and graft outcome in simultaneous pancreas-kidney transplantation.

作者信息

Petruzzo Palmina, Lefrancois Nicole, Berthillot Celine, Danjou Fabrice, Contu Paolo, Codas Ricardo, Morelon Emmanuel, Dubernard Jean Michel, Martin Xavier, Badet Lionel

机构信息

Service d'Urologie et Chirurgie de la Transplantation, Hôpital Edouard Herriot, Lyon, France.

出版信息

Clin Transplant. 2008 Jan-Feb;22(1):107-12. doi: 10.1111/j.1399-0012.2007.00773.x.

Abstract

The impact of portal or systemic venous pancreas graft drainage on patient and graft outcome remains controversial. In the present study, the impact of venous drainage type on long-term patient and graft survival is assessed. From July 1996 to December 2002 80 simultaneous pancreas-kidney transplants were enrolled into a prospective study: 44 received a pancreas allograft with portal (P-SPK group) and 36 with systemic venous drainage (S-SPK group). Enteric exocrine drainage was performed in all recipients receiving the same immunosuppressive treatment. At one yr, the patient survival rates were 91.7% and 95.5% both for S-SPK and P-SPK groups, respectively; no significant difference in survival was shown at any time point of the follow-up. The one-, three-, five-, and eight-yr pancreas survival rates were 75%, 60.6%, 56.7%, and 44%, respectively in the S-SPK group compared to 88.6%, 84.1%, 78.4%, and 31.3% in the P-SPK group. The one-, three-, five-, and eight-yr kidney survival rates were 91.7%, 78.15%, 74.1%, and 57.9%, respectively in the S-SPK group compared to 93.2%, 88.6%, 78.4%, and 38.9% in the P-SPK group. Comparing the two groups, no significant difference was shown in the total number of surgical complications as well as in the number of each complication. No significant difference in long-term outcomes between the two groups was shown, even if in S-SPK group a higher incidence of pancreas graft loss has been reported and it was in part correlated to a higher number of graft thromboses.

摘要

门静脉或体静脉胰腺移植引流对患者及移植物预后的影响仍存在争议。在本研究中,评估了静脉引流类型对患者长期生存及移植物存活的影响。1996年7月至2002年12月,80例同期胰肾联合移植患者纳入一项前瞻性研究:44例接受门静脉引流的胰腺同种异体移植(P-SPK组),36例接受体静脉引流(S-SPK组)。所有接受相同免疫抑制治疗的受者均采用肠内胰外分泌引流。1年时,S-SPK组和P-SPK组患者生存率分别为91.7%和95.5%;随访的任何时间点均未显示出生存率的显著差异。S-SPK组1年、3年、5年和8年的胰腺生存率分别为75%、60.6%、56.7%和44%,而P-SPK组分别为88.6%、84.1%、78.4%和31.3%。S-SPK组1年、3年、5年和8年的肾脏生存率分别为91.7%、78.15%、74.1%和57.9%,而P-SPK组分别为93.2%、88.6%、78.4%和38.9%。比较两组,手术并发症总数及每种并发症数量均未显示出显著差异。两组长期预后未显示出显著差异,尽管S-SPK组报告的胰腺移植物丢失发生率较高,且部分与较高的移植物血栓形成数量相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验